Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.
about
Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case reportPopulation pharmacokinetic-pharmacodynamic analysis of fluindione in patients.Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptylineHidden cardiac lesions and psychotropic drugs as a possible cause of sudden death in psychiatric patients: a report of 14 cases and review of the literature.Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.Aging and clinical pharmacology: implications for antidepressants.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.Sex differences in pharmacokinetics of antidepressants.Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂.Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
P2860
Q21202079-C5380B88-686E-45D2-BF8D-93D12B4F7881Q34065956-3B125BDD-AA41-430C-9E7B-645D8680C2CCQ34250313-CD7E111E-B16D-430E-97E4-63FC49ED383BQ34597852-BE230260-D3FB-4AE6-A29D-4E1A8345F915Q35738824-071CEDE8-8BF2-4E2C-AB4E-D3912834B3C0Q36053742-5F56F798-DEEF-4A62-AFB5-0E5EE103BD92Q36261418-4F97CFA1-539E-4064-8647-C8EC765B2D99Q36628026-5D38F440-A82B-4D41-A9C1-0216E08F1FFAQ37236959-5149FEF5-078C-48C9-A6CB-FEACF5F5F0A6Q37824711-89B9AED7-3492-4586-96CF-44728F1FC820Q48385208-2C92CA29-DDCF-4C8E-BC75-28F0E6BD233AQ51000121-4BE9CB95-1571-4A34-93BB-A0EE1939630E
P2860
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Population pharmacokinetics of ...... ric maximum likelihood method.
@ast
Population pharmacokinetics of ...... ric maximum likelihood method.
@en
Population pharmacokinetics of ...... ric maximum likelihood method.
@nl
type
label
Population pharmacokinetics of ...... ric maximum likelihood method.
@ast
Population pharmacokinetics of ...... ric maximum likelihood method.
@en
Population pharmacokinetics of ...... ric maximum likelihood method.
@nl
prefLabel
Population pharmacokinetics of ...... ric maximum likelihood method.
@ast
Population pharmacokinetics of ...... ric maximum likelihood method.
@en
Population pharmacokinetics of ...... ric maximum likelihood method.
@nl
P2093
P2860
P1476
Population pharmacokinetics of ...... ric maximum likelihood method.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1994.TB04382.X
P407
P577
1994-11-01T00:00:00Z